Development of human neuroblastoma is due to an arrest in the dierentiation program of neural crest sympathoadrenal progenitor cells. However, neuroblastomas, as well as their derived cell lines, maintain the potentiality of terminal dierentiation. We investigated the molecular mechanisms by which retinoic acid, a molecule introduced in clinical trials for chemotherapy, induces dierentiation in neuroblastoma cell lines. Our ®ndings demonstrate that the retinoic acid-dependent growth arrest of LAN-5 neuroblastoma cell line is associated to a very large accumulation (>tenfold) of p27 Kip1 protein, a cyclin-dependent kinase inhibitor; the protein binds and inhibits cyclin-dependent kinase 2, 4 and 6 activities, thus hampering pRb and p107 phosphorylation. p27 Kip1 build-up was observable as an early phenomenon (12 ± 24 h) after retinoic exposure and resulted in a time-dependent accumulation of high quantities of a free p27
Kip1 form. Furthermore, retinoic treatment causes an increase of cyclin-dependent kinase 5 level and activity; however, immunoprecipitation studies proved the absence of interaction with p27 kip 1 . No noticeable variation of other components of G1 phase cell cycle engine was observed. Pulse-chase experiments showed a remarkable elongation of p27
Kip1 half-life in retinoic-treated LAN-5, while no enhancement of p27 Kip1 gene expression and of the translational eciency of its messenger RNA were demonstrated. In vivo degradation of p27
Kip1 was sensitive to two highly speci®c proteasome inhibitors, LLnL and lactacystin, while the calpain inhibitor II ALLM and the cysteine protease inhibitor E64 did not modify the level of the protein. LLnL treatment caused a very rapid (2 h) build-up of the Cdk inhibitor content and the accumulation of higher molecular weight anti-p27 Introduction Neuroblastoma, one of the most frequent neoplasms of infancy, is associated with a very poor long-term survival in patients with high-risk disease (Pinkerton, 1993) . The therapeutic approach of advanced cases combines surgical resection with radiation therapy and chemotherapy (Philip and Pinkerton, 1989) . Recently there has been growing attention in the potential clinical use of drugs able to induce dierentiation of neuroblastoma cells. Among the numerous molecules tested, all-trans retinoic acid (RA) appears a promising candidate, since it causes in vitro dierentiation of neuroblastoma cell lines along dierent (neuronal-or schwannian-like) lineages, depending on the employed cell line (Khan et al., 1996) .
Although the control of terminal dierentiation is probably mediated by multiple and possibly redundant mechanisms, cell division cycle arrest is likely to be a key event of the process. Therefore, the eect of RA on cell growth engine during neuroblastoma differentiation appears of noticeable interest, also in view of its therapeutical application.
In eukaryotes, cell cycle progression requires an ordered activation of multiple cyclin-dependent serinethreonine kinases (Cdks) by binding with dierent speci®c cyclins (Sherr, 1994) . Then, the activated Cdks regulate their target molecules by phosphorylation, and in turn, these downstream molecules carry out the steps which ultimately allow the precise development of a cell division round (Sherr, 1994) . Thus, the regulation of Cdk activity is the critical event in cell cycle progression.
The levels of the various Cdk proteins generally do not remarkably vary during the cycle, while the amount of each cyclin undergoes dramatic changes. Progression from G1 to S phase requires the build-up of cyclin Ds and E and their binding to the Cdk4 (or Cdk6) and Cdk2, respectively. However, interaction between a Cdk and its speci®c cyclin partner is not sucient alone to activate the holoenzyme, since positive and negative regulation of Cdk activity also includes phosphorylation at speci®c amino acid residues (Elledge et al., 1996) .
Equally important in the regulation of Cdk kinase activity is the level of small inhibitors belonging to two dierent classes, namely INK4 (including p16 Harper et al., 1993), p27 Kip1 (Polyak et al., 1994a; Toyoshima and Hunter, 1994 ) and p57
Kip2 (Lee et al., 1995) ; they associate with the catalytic Cdk subunit and the cyclin partner to form multi-subunit complexes including several additional proteins (Elledge et al., 1996) . Possible biological roles of the inhibitors belonging to the CIP/Kip family include regulation of cell cycle entry (or exit) during several phenomena (like cell-to-cell contact inhibition and reversible or terminal dierentiation) (Polyak et al., 1994b; Kato et al., 1994) and control of the progression through the phases of a division round (Coats et al., 1996) . Moreover, since p21 CIP1 gene expression is also (but not exclusively) under p53 transcriptional control, this protein (but not p27
Kip1 or p57
Kip2
) is a p53 eector molecule (Harper et al., 1993) .
Since the main role of the Cdk inhibitors is to act as intrinsic brakes of cell cycle engine at critical moments of cell life, intense debates exist about the molecular mechanisms regulating their levels. p21 CIP1 cellular concentration is regulated mainly at transcriptional level, being its gene under the control of dierent transcriptional factors including p53 (ElDeiry et al., 1993) and C/EBP (Timchenko et al., 1996) . Conversely, p27
Kip1 levels are thought to be regulated by post-transcriptional processes. Particularly, two mechanisms have been proposed: (i) modulation of mRNA translation eciency (Hengst and Reed, 1996) and (ii) regulation of protein degradation rate, controlled by a mechanism involving the ubiquitin/proteasome pathway (Pagano et al., 1995) . Moreover, it has been suggested that p27
Kip1 ubiquitination requires initial phosphorylation step(s) (possibly due to cyclinE/Cdk2 active complex or other serine/threonine kinases), which commit(s) the protein to proteolytic removal (Alessandrini et al., 1997) .
In this study we sought to clarify the mechanisms by which RA induces neuroblastoma cells to cease dividing and dierentiate. In particular, we investigated the modi®cation occurring at G1 phase of cell cycle engine. Our results point to a rapid increase of p27 Kip1 as a central mechanism of RA growth restraining activity and to the inhibition of p27 Kip1 degradation as the molecular basis of this build-up.
Results
Induction of cell cycle arrest and dierentiation by RA in neuroblastoma cell lines LAN-5 neuroblastoma cell line was incubated in the presence of 5 mM RA and the morphological changes were followed for 6 days. After 48 h, the cells began to show phenotypical changes, assuming a neuronal-like morphology with contemporaneous formation of dendritic-like structures (Figure 1a,b) . At the same time (2 days), a decrease of the proliferation rate was observable along with a small accumulation of cells in G1 phase, as demonstrated by¯ow cytometric analysis (Figure 1c ). Thereafter (from 2 ± 6 days), a progressive increase of G1 phase cells was observed (Figure 1c) . A similar eect of RA on cell proliferation was obtained studying two additional neuroblastoma cell lines, namely IMR-32 and SK-N-SH.
Eect of RA on G1 phase cell division cycle engine Since RA treatment induces a G1 phase arrest, cell extracts were prepared from LAN-5 cells exposed to the dierentiating agent for 2, 4 and 6 days and analysed by immunoblotting for the Cdk inhibitor levels. As reported in Figure 2, (Figure 2 ).
More detailed time-course experiments (Figure 3a ,b) demonstrated that p27
Kip1 build-up occurs after 24 h treatment, reaching a tenfold increase after 48 h. We also examined the eect of dierent amounts of RA on p27 Kip1 cellular levels. As shown in Figure 3c , the lowest all-trans RA concentration increasing p27
Kip1 contents was 0.5 mM. The eect of 9-cis RA on p27
Kip1 contents was also analysed (Figure 3c ). This molecule appeared even more ecacious than the all-trans isomer, being already active at 100 nM concentration.
Immunoblotting analyses of other G1 phase cell division cycle proteins demonstrated that levels of cyclin Ds, cyclin E, cyclin A, Cdk2, Cdk4 and Cdk6 did not show signi®cant alterations after 48 h from RA addition. Almost all these proteins were equally expressed in LAN-5 cells, both during proliferation and RA-induced dierentiation (data not reported). Conversely, since preliminary experiments showed an increase of Cdk5 during RA treatment, we carried out a detailed analysis of this kinase over a 6 day-period. As shown in Figure 3d , a clear build-up of Cdk5 was observable after 4 days treatment. Moreover, determination of the kinase activity on a-Cdk5 immunoprecipitates demonstrated an activity enhancement which was roughly proportional to the protein content (data not shown).
Since the accumulation of p27 Kip1 might impair Cdk2 and Cdk4 activities, we studied the phosphorylation degree of the retinoblastoma protein, pRb, and its p107 homologue, key substrates of the G1-Cdks. pRb and p107 phosphorylation status was analysed by immunoblotting, since hyperphosphorylated inactive forms migrate on SDS ± PAGE more slowly than the active hypophosphorylated forms do. As shown in Figure 3e , a clear time-dependent impairment of pRb and p107 phosphorylation was observed after RA addition to LAN-5 cells.
Next, we analysed the eect of RA on p27
INK4A and p18 INK4C levels in IMR-32 and SK-N-SH cells (data not reported). Both IMR-32 and SK-N-SH showed a remarkable increase of p27 Kip1 levels after 2 days of RA treatment. Conversely, none of the other inhibitors analysed (namely p21 CIP1 , p16
INK4A and p18
INK4C
) could be detected or showed any build-up. These results con®rm the p27
Kip1 build-up during RAinduced cell growth impairment in neuroblastoma cell lines.
Characterization of p27

Kip1 -containing complexes
As reported above, when LAN-5 cells were treated with RA, a remarkable increase of p27
Kip1 protein was , while a-Cdk2 immunoprecipitated proteins very scarcely reacted with a-p27
Kip1 monoclonal antibodies. When a-Cdk4 and a-Cdk6 immunoprecipitates from RA-treated extracts were analysed for p27
Kip1 content, an increase of about twofold was evidenced with respect of control cells. Conversely, a very noticeable p27
Kip1 build-up (4tenfold of control) was detected in anti-Cdk2 immunoprecipitate ( Figure  4a ).
These results suggested that p27 Kip1 is, in control cells, bound almost exclusively to Cdk4 and Cdk6. On the contrary, in RA-treated cells a high amount of the Cdk inhibitor interacts with Cdk2. In order to verify this hypothesis, we immunoprecipitated LAN-5 extracts with a-Cdk4 plus a-Cdk6 antibodies (Figure 4b ).
The analysis of supernatants indicated that more than 85% of p27
Kip1 was associated with Cdk4 and Cdk6 in control cells, while less than 15% of p27
Kip1 interacts with these kinases in RA-treated cells.
To clarify further the interaction between p27 Kip1 and Cdk2 before and after RA treatment, we immunoprecipitated cell extracts using amounts of a-p27 Kip1 antibodies which totally precipitated the protein. As reported in Figure 4c , the a-p27
Kip1 immunoprecipitate obtained from the RA-treated cells contained mostly of the cyclin E content and all the active (faster migrating) form of Cdk2. The analysis of the supernatant showed that the inactive (slower migrating) form of Cdk2 protein was scarcely precipitated by ap27 Kip1 antibodies. Subsequently, we analysed the interaction between p27
Kip1 and Cdk5. Although a great amount of this kinase was found in LAN-5 cell extracts (see Figure  3d ), Cdk5 did not co-immunoprecipitate with p27 Kip1 (Figure 4d ), thus demonstrating the complete absence of p27
Kip1 and Cdk5 interaction. The observed increase of Cdk2/cyclin E/p27 Kip1 and Cdk4(or Cdk6)/cyclin D/p27 Kip1 complexes in RAtreated cells might inhibit the respective kinase activities, thus explaining the rapid decrease of pRb and p107 phosphorylation and the impairment of growth. To con®rm this hypothesis, we assayed the kinase activity of a-Cdk2 and a-Cdk4 immunoprecipitates by using histone H1 (Cdk2) or pRb (Cdk4) as speci®c protein substrates. As shown in Figure 4e , after 48 h of RA treatment, no Cdk2 activity was detectable. At the same time-period, a decrease of about 60 ± 70% of Cdk4 activity was observable in RA-treated cells compared to control cells (data not shown).
The ®ndings reported in Figure 4 suggested the occurrence, in RA-treated LAN-5 cells, of a remarkable p27
Kip1 fraction which is not precipitated by antibodies against G1 Cdks and which could be in a free form. To evaluate this hypothesis, we exploited a method based on a gel-®ltration chromatographic separation of cell extracts followed by immunoblotting analysis of each fraction (Della Ragione et al., 1996) . The technique employs a Superdex-75 HR column, which provides a very high resolution in a molecular mass range lower than 80 kDa.
As reported in Figure 5a , the chromatographic separation of extracts from untreated LAN-5 cells showed p27
Kip1 eluted with the void volume (fractions 28 ± 30). Conversely, the extract from cells treated for 2 days with RA revealed the occurrence of a high amount (470%) of free p27
Kip1 (fractions 42 ± 46). We con®rmed that the protein was in a free status since it eluted at the same Kav of recombinant p27
Kip1 and of Kip1 accumulation in neuroblastoma differentiation A Borriello et al the protein obtained from boiled extracts (data not shown). Indeed, it was previously demonstrated that a 5 min treatment at 1008C releases active p27 Kip1 from complexes containing the Cdk inhibitor (Hengst et al., 1994) . In the same experiment, we also demonstrated that a large amount (more than 90%) of Cdk2 and Cdk4 and the whole cyclin E and D3 content eluted at the void volume of the column, corresponding to a molecular weight higher than 80 kDa (Figure 5a , and data not shown).
Subsequently, extracts from LAN-5 cells treated for dierent time periods with retinoic acid were fractionated on a Superose 6 which resolves molecules with higher molecular weight (Figure 5b) . By this methodology, we established at each times the percentage of the free (eluting in fractions from 32 ± 36) and the associated (eluting in fractions 26 ± 28) forms of p27 Kip1 (Figure 5c ). Moreover, we established that bound p27
Kip1 eluted concomitantly with Cdk2 and cyclin E, thus con®rming the results obtained from the immunoprecipitation experiments. The complexes have a molecular mass of about 200 kDa, suggesting the possible occurrence of proteins other than cyclin, Cdk and the Cdk inhibitor.
Molecular mechanisms of p27
Kip1 increase
The observed build-up of p27 Kip1 in RA-treated LAN-5 could be due to: (i) an increased gene transcription; (ii) a higher eciency of mRNA translation and (iii) a decrease of proteolytic degradation. Northern blot analyses (Figure 6a ) and quantitative RT ± PCR experiments (data not shown) indicated that no variation in p27
Kip1 mRNA content occurred after 48-h of RA-treatment. Therefore, p27
Kip1 accumulation could be ascribed to post-transcriptional mechanisms including a higher translational eciency or a downregulation of protein removal.
In order to evaluate the relative importance of these two processes, we calculated the half-life of p27
Kip1 in control and RA-treated cells. As shown in Figure 6b , Kip1 antibodies. The immunoprecipitated proteins (IP) and the supernatants (SUP) were then analysed by using antibodies against Cdk2. The immunoreactive bands were visualized by ECL detection system using a very short (15 s) exposition time in order to clearly detect both the faster migrating active Cdk2 band (pCdk2) and the slower migrating inactive Cdk2 form (Cdk2). (d) Extracts from RA-treated LAN-5 were immunoprecipitated either by anti-p27
Kip1 (a-p27) serum or normal rabbit serum (NRS). Then, supernatants (SUP) and immunoprecipitated complexes (IP) were analysed by antibodies against CDK5. (e) Extracts from LAN-5 cells treated for dierent time with RA (0, 24 and 48 h) were immunoprecipitated by anti-Cdk2 (a-CDK2) serum. The immunoprecipitates were assayed for Cdk2 kinase activity p27 Kip1 accumulation in neuroblastoma differentiation A Borriello et al an half-life elongation (from 2.5 h to 45 h) was demonstrable, without variation, between treated and untreated cells, in the incorporation of radioactivity (determined by laser scanning of the¯uorography) after 1 h labeling. These data ruled out a dierent translational eciency of p27
Kip1 mRNA and pointed to a decrease in the protein removal as the major mechanism of the inhibitor accumulation.
Subsequently, to characterize the mechanism of p27 Kip1 degradation, we added dierent permeable protease inhibitors to growing LAN-5 cells. We used two highly speci®c proteasome inhibitors, namely lactacystin and N-acetyl-leucinyl-leucinylnorleucinal-H (LLnL), the calpain inhibitor II (N-acetyl-leucinylleucinylmethional, ALLM) and the cysteine protease inhibitor 2S,3S-trans-(carboxyoxirane-2-carbonyl)-Lleucine-agmatine (E64). As shown in Figure 7a , the two proteasome inhibitors caused a remarkable increase of p27
Kip1 cellular content, while both ALLM and E64 did not modify the Cdk inhibitor levels. A prolonged exposition of immunoblots revealed the occurrence of p27 Kip1 -related bands with higher molecular mass, particularly in LLnL treated cells (Figure 7b ). These immunoreactive signals were probably due to the accumulation of p27
Kip1 -ubiquitinated forms. We also performed a time course analysis of the LLnL eect on p27
Kip1 levels. As shown in Figure 7c , after only 2 h of incubation a new steadystate of p27
Kip1 content was reached, thus con®rming the rapid turn-over of the protein and the pivotal role of proteasome-dependent degradation in the control of its intracellular levels.
Since LLnL causes an accumulation of p27 Kip1 by interfering with the removal of the protein, we wondered whether the addition of the proteasome inhibitor further enhanced the accumulation of p27 Kip1 in RA-treated LAN-5. As shown in Figure 7d , while a remarkable increase of p27
Kip1 was observable after (Figure 7d ). This result suggested to us that RA and LLnL might increase the Cdk inhibitor levels by acting on a common target, namely the ubiquitination/proteasome degradation pathway.
Subsequently, we evaluated the in vitro p27
Kip1 degradation capability of extracts from LAN-5 cells cultured in the presence or in the absence of the dierentiating agent for 1 or 2 days. As reported in Figure 8a , a strong dierence was observable among the dierent extracts. In fact, while 100 mg protein of extracts from growing cells (either after 1 or 2 days of culture) were able to completely degrade 1 mg of recombinant p27 Kip1 in 30 min, the same amount of proteins from two days RA-treated cells employed more than 2 h to remove only 50% of the protein. A remarkable down-regulation of p27
Kip1 degradation rate was already observable using the extract prepared after 1 day of retinoic acid incubation. Superimposable results were obtained employing extracts from SK-N-SH and IMR-32 cell lines (data not shown).
Control experiments, carried out preincubating the extract from growing cells with LLnL, showed the absence of p27 Kip1 removal, con®rming that the degradation requires LLnL-sensitive proteolitic sys- Kip1 accumulation in neuroblastoma differentiation A Borriello et al tems (data not reported). More interestingly, addition of an extract from untreated cells to a RA-treated cell extract resulted in an increase of the degrading activity, thus suggesting that cells cultured for 48 h in the presence of RA lack (completely or partially) some components of p27 Kip1 proteolitic pathway (Figure 8b ).
Discussion
In the present paper we investigated the eect of RA, a compound introduced in the therapy of dierent cancers, on the cell cycle engine of three neuroblastoma cell lines. Since RA causes growth impairment with progressive accumulation of cells in G1 phase, we studied the protein machinery responsible for G1-4S transition.
When we analysed RA-treated LAN-5 cells, we observed an early (12 ± 24 h) and remarkable (4tenfold in 48 h) increase of p27
Kip1 , a Cdk-inhibitor. None of the other G1 phase speci®c protein components showed important level variations. These results clearly point to p27
Kip1 as a critical factor in inducing the cell growth restrain required for RA-dependent dierentiation.
Interestingly, we also observed a signi®cant increase of Cdk5 protein and activity at 4 ± 5 days after addition of RA to LAN-5 cells (Figure 3d ). Cdk5 is involved in cellular maturation, and particularly in neuronal dierentiation, by phosphorylating a number of dierent proteins (Dongming et al., 1996) . In addition, immunoprecipitation experiments clearly demonstrated that Cdk5 did not bind p27
Kip1 and thus, its activity was not aected by the remarkable build-up of the Cdk inhibitor.
The data obtained in LAN-5 cells were also con®rmed using two additional cell lines, namely IMR-32 and SK-N-SH. These ®ndings allowed additional conclusions. First of all, the increase of p27 Kip1 , observed in LAN-5, is probably a general response of neuroblastoma (and other tumor) cells to RA. Furthermore, since IMR-32 cells treated with RA cease to divide but do not dierentiate (Murakami et al., 1991) , the accumulation of p27 Kip1 might be required only for the RA-dependent growth arrest, which is necessary (but not sucient) to cellular dierentiation. Thus, the lineage program (when occurring) is dependent upon the regulation of further pathways and is probably related to the cellular type and to the stage of development arrest.
The other cell line studied, SK-N-SH, showed cell growth arrest and neuronal-like dierentiation after RA-addition. This cell line, however, does present neither ampli®cation of N-myc gene nor its expression (Thiele et al., 1985) . High levels of N-myc protein (due to ampli®cation of its gene on 1p chromosome) are believed to have an important negative prognostic value in neuroblastoma. One of the main molecular eects of RA-treatment is the down-regulation of Nmyc expression which has been demonstrated in vitro in several neuroblastoma cell lines, but obviously not in SK-N-SH cells (Thiele et al., 1985) . In our experiments, we observed the accumulation of p27
Kip1 independently upon the expression or down-regulation of N-myc gene, thus allowing the conclusion that N-myc levels are not directly involved in pathway(s) controlling p27
Kip1 content. This result is of interest since a clear inverse relationship between c-myc (a dierent member of myc family) and p27
Kip1 levels has been reported (Vlach et al., 1996) .
The mechanism by which p27 Kip1 inhibits cell proliferation seems to be the binding to Cdk2 and Cdk4(Cdk6)-containing complexes with the subsequent inhibition of these kinase activities. The results reported in Figure 4 suggested that the small amount of p27
Kip1 occurring in untreated cells is bound almost completely to Cdk4 and Cdk6. After RA treatment, the p27
Kip1 build-up results in a moderate increase of interaction with Cdk4 and Cdk6 (causing a reduction of kinase activity) and in an extensive binding of the inhibitor to the active form of Cdk2. The inhibition of G1 Cdk activities results in the accumulation of both pRb and p107 in a hypophosphorylated active status, and, in turn, in the G1 phase cell cycle arrest.
In analysing p27
Kip1
-containing complexes occurring in RA-treated LAN-5 cells, we surprisingly discovered that an enormous percentage of this protein (470%) is in a free status. The occurrence of p27
Kip1 in a free form was unexpected since, although very few experiments have been carried out on this feature (Hengst et al., 1994) , we thought to ®nd all p27
Kip1 bound to Cdkcontaining complexes. The presence of high amount of free p27
Kip1 in RA-treated cells suggests that under this condition the Cdk inhibitor synthesis strongly exceeds its degradation rate. Moreover, growing LAN-5 cells Kip1 accumulation in neuroblastoma differentiation A Borriello et al treated with the proteasome-speci®c inhibitor LLnL accumulated very rapidly (2 h, Figure 7c ) a remarkable amount of p27 Kip1 protein, reaching a new steady state for the Cdk inhibitor. Thus, these results point to the proteolytic removal as a primary mechanism in controlling p27 Kip1 level. An alternative and interesting possibility, which could explain the presence of large amounts of the free protein, is that the complete inhibition of Cdk2 kinase activity hampers the phosphorylation of p27
Kip1 itself (Shea et al., 1997; Vlach et al., 1997) , thus causing the accumulation of the inhibitor in a form which is not degradable via the phosphorylation-ubiquitination-proteasome digestion pathway (Alessandrini et al., 1997) .
One of the major results of our investigation is that RA-treatment of neuroblastoma cell lines induces growth arrest by reducing the rate of p27 Kip1 degradation. This conclusion is supported by several ®ndings including: (i) the elongation of the protein half-life in the RA-exposed cells; (ii) the accumulation of p27
Kip1 in cells treated with LLnL and lactacystin, and (iii) the enormous decrease in the p27
Kip1 proteolitic activity showed by RA-treated neuroblastoma cells compared to control LAN-5 cells observed in the in vitro degradation experiments.
Our ®ndings indicate that very early (about 24 h) after RA addition, it is possible to observe an in vitro impairment of p27
Kip1 degradation. It must be underlined that at this time-period the eect on cell proliferation (or dierentiation) was minimal and thus the down-regulation of p27
Kip1 removal is not simply a consequence of a G1-block or of a phenotypical change.
The p27 Kip1 degrading activity was inhibited both in vivo ( Figure 7 ) and in vitro (data not shown) by proteasome speci®c inhibitors, thus indicating that the process is ubiquitin/proteasome-dependent. This is also con®rmed by the absence of eects of calpain and cysteine protease inhibitors (Figure 7a ) and by the presence of putative p27 Kip1 -ubiquitinated forms after proteasome inhibitor treatment (Figure 7b ). Interestingly, the addition of extracts derived from growing cells to RA-treated cell extracts was able to complement the reduced p27
Kip1 removing ability of differentiated neuroblastoma cells (Figure 8b ). This ®nding permits to rule out the expression, in the last sample, of proteasome pathway inhibitor(s) and suggests the absence (relative or absolute) of some components of the proteolytic machinery.
In conclusion, our ®ndings demonstrate that RA treatment induces the accumulation of p27 Kip1 as consequence of a block in the degradation of this protein. Then, the Cdk inhibitor causes growth impairment and, depending on the employed cell line, the activation of a dierentiation program. Although it has been reported that in some cell lines p27 Kip1 increase might be due to the activation of gene transcription (Liu et al., 1996) , it is widely accepted that the level of this inhibitor is generally controlled at post-translational level. However, our data represent the ®rst demonstration that an antiproliferative agent (i.e. RA) might regulate p27 Kip1 levels by downmodulating its proteasoma-dependent removal. This eect is observable before the G1 phase arrest and thus it does not depend on the accumulation of cells in a quiescent condition. Since it has been recently described (Zancai et al., 1998) that RA causes p27 Kip1 accumulation in cell type dierent from neuroblastoma cells, our data suggest a novel mechanism of retinoic antiproliferative action (i.e. the impairment of p27 Kip1 degradation). Furthermore, being this mechanism operative for both RA isomers (all-trans and 9-cis), future studies should also clarify the retinoic receptor types required for the cell division cycle block. Cell culture, preparation of cell extracts and immunoblotting LAN-5, IMR-32 and SK-N-SH cell lines were grown as reported in Della Ragione et al., 1995. Flow cytometric analyses were carried out as described in Nicoletti et al., 1991 . Cell extracts were prepared as described in Della Ragione et al., 1995 Ragione et al., , 1996 . Immunoblotting analyses were performed as reported in Della Ragione et al., 1996. Generally, 20 ± 80 mg proteins were separated by SDS ± PAGE. After blotting and incubation with antibodies, the immunoreactive bands were visualized by ECL detection system, taking dierent exposition times in order to evaluate the reproducibility and proportionality of the signals. The relative intensity of each signal was determined by laser scanner densitometric analysis using a Pharmacia/LKB Ultroscan XL.
Materials and methods
Materials
Immunoprecipitations, labeling experiments and kinase assays
Immunoprecipitations were carried out with 0.5 ± 1 mg of lysate protein aliquots and subjected to Western blotting as in Della Ragione et al., 1996. In the case of p27 Kip1 , immunoprecipitation was performed by using rabbit polyclonal antibodies generated against the amino acids 181 ± 198 of human p27
Kip1 sequence (sc-528, Santa Cruz). LAN-5 cells were labeled as reported in Hengst and Reed, 1996 . After the labeling, protein concentrations were determined and equal amounts of protein were boiled for 10 min. The heat-stable supernatant, containing almost all p27
Kip1 protein was immunoprecipitated by using the sc-528 antiserum. The immunocomplexes were collected on Protein A-Sepharose beads (Sigma) and washed seven times in lysis buer. The immunoprecipitated proteins were separated by SDS ± PAGE, treated with Amplify (Amersham) and used for auto¯uorography.
Cdk2 and Cdk4 activities were determined as in , while Cdk5 activity as described in Dongming et al., 1996 .
RNA preparation and analysis
Total RNA was prepared as reported in Chomeczynski and Sacchi, 1987 . 10 mg RNA were used for Northern blotting p27 Kip1 accumulation in neuroblastoma differentiation A Borriello et al analysis by employing human p27
Kip1 and GAPDH probes, (Iolascon et al., 1998) . Moreover, 0.5 mg RNA were reverse transcribed, and the obtained cDNA was PCR ampli®ed to analyse the expression of p27
Kip1 (Iolascon et al., 1998) .
Protein extract fractionation on gel ®ltration chromatography 500 ml cellular extracts (2 ± 10 mg proteins) were fractionated either on a Superdex-75 HR column or on a Superose 6 column (Pharmacia, Uppsala, Sweden) as described in Della Ragione et al., 1995. The fractions were added with a protease inhibitor cocktail and left at 48C when immediately analysed, or at 7808C when stored for prolonged time periods. Aliquots (40 ml) of the fractions were directly analysed by immunoblotting, but, when the expected signals were lower than the ECL detection limit, samples were precipitated by trichloroacetic acid, washed with acetone/ NH 4 OH mixture, resuspended in loading electrophoresis sample buer and analysed by immunoblotting.
In Vitro p27 Kip1 degradation experiments His 6 -tagged mouse p27 Kip1 was prepared and puri®ed by anity chromatography on Ni 2+ -nitrilotriacetic acid (NiN-TA)-agarose following manufacturer's instructions (Novagen). The ability of cell extracts of degrading puri®ed His 6 -tagged p27
Kip1 was evaluated exactly as reported by Loda et al., 1997. In some experiments, the complete assay mixture (without ubiquitin and recombinant p27 Kip1 ) was preincubated with or without 50 mM LLnL for 30 min in an ice bath.
